Clinical Trial

RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated April 10, 2024 (before its estimated September 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
an open, single-arm, multicenter phase Ib/II study
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-04-18; most recent amendment 2024-04-09.
Status change: Not Yet Recruiting → Recruiting 2023-11-24
Trial Details
NCT Number NCT05821933
Lead Sponsor RemeGen Co., Ltd.
Conditions NSCLC
Enrollment 106 participants
Start Date 2023-09-07
Primary Completion 2025-09-01 (estimated)
Study Completion 2026-09-01 (estimated)
Updated on ClinicalTrials.gov 2024-04-10